Welcome to our dedicated page for Theratechnologies news (Ticker: THTX), a resource for investors and traders seeking the latest updates and insights on Theratechnologies stock.
Theratechnologies Inc (NASDAQ: THTX) is a specialty biopharmaceutical company advancing therapies for HIV complications and oncology conditions. This news hub provides investors and medical professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Access timely information about FDA-approved HIV treatments like EGRIFTA for lipodystrophy and Trogarzo for multidrug-resistant infections, alongside emerging oncology candidates targeting aggressive cancers. Our curated news collection includes earnings reports, partnership announcements, and research breakthroughs.
Key updates cover three focus areas: commercialized HIV therapies, pipeline progress in oncology, and operational developments across North American/European markets. Content types include clinical trial results, regulatory filings, and executive commentary.
Bookmark this page for structured access to Theratechnologies' latest advancements in niche biopharmaceutical solutions. Verify information directly through company filings and press releases for informed decision-making.
Theratechnologies will present long-term efficacy, safety, and pharmacokinetic data on the use of TH1902 in solid tumors at the 2024 ASCO Meeting. The presentation will focus on the Phase 1 clinical trial of sudocetaxel zendusortide in patients with cancers that have high SORT1 expression. Part 3 of the trial in advanced ovarian cancer is ongoing, providing valuable insights into the novel peptide-drug conjugate.
FAQ
What is the current stock price of Theratechnologies (THTX)?
What is the market cap of Theratechnologies (THTX)?
